These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

166 related articles for article (PubMed ID: 11748267)

  • 1. Antisense inhibition of macrophage inflammatory protein 1-alpha blocks bone destruction in a model of myeloma bone disease.
    Choi SJ; Oba Y; Gazitt Y; Alsina M; Cruz J; Anderson J; Roodman GD
    J Clin Invest; 2001 Dec; 108(12):1833-41. PubMed ID: 11748267
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Significance of macrophage inflammatory protein-1 alpha (MIP-1alpha) in multiple myeloma.
    Terpos E; Politou M; Viniou N; Rahemtulla A
    Leuk Lymphoma; 2005 Dec; 46(12):1699-707. PubMed ID: 16263571
    [TBL] [Abstract][Full Text] [Related]  

  • 3. MIP-1 alpha and myeloma bone disease.
    Roodman GD; Choi SJ
    Cancer Treat Res; 2004; 118():83-100. PubMed ID: 15043189
    [TBL] [Abstract][Full Text] [Related]  

  • 4. MIP-1alpha utilizes both CCR1 and CCR5 to induce osteoclast formation and increase adhesion of myeloma cells to marrow stromal cells.
    Oba Y; Lee JW; Ehrlich LA; Chung HY; Jelinek DF; Callander NS; Horuk R; Choi SJ; Roodman GD
    Exp Hematol; 2005 Mar; 33(3):272-8. PubMed ID: 15730850
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Inhibition of BDNF in multiple myeloma blocks osteoclastogenesis via down-regulated stroma-derived RANKL expression both in vitro and in vivo.
    Ai LS; Sun CY; Zhang L; Zhou SC; Chu ZB; Qin Y; Wang YD; Zeng W; Yan H; Guo T; Chen L; Yang D; Hu Y
    PLoS One; 2012; 7(10):e46287. PubMed ID: 23077504
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Bone disease in multiple myeloma and its mechanism].
    Abe M
    Clin Calcium; 2006 Apr; 16(4):565- 71. PubMed ID: 16582506
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Role for macrophage inflammatory protein (MIP)-1alpha and MIP-1beta in the development of osteolytic lesions in multiple myeloma.
    Abe M; Hiura K; Wilde J; Moriyama K; Hashimoto T; Ozaki S; Wakatsuki S; Kosaka M; Kido S; Inoue D; Matsumoto T
    Blood; 2002 Sep; 100(6):2195-202. PubMed ID: 12200385
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Dual effects of macrophage inflammatory protein-1alpha on osteolysis and tumor burden in the murine 5TGM1 model of myeloma bone disease.
    Oyajobi BO; Franchin G; Williams PJ; Pulkrabek D; Gupta A; Munoz S; Grubbs B; Zhao M; Chen D; Sherry B; Mundy GR
    Blood; 2003 Jul; 102(1):311-9. PubMed ID: 12649140
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Development of an in vivo model of human multiple myeloma bone disease.
    Alsina M; Boyce B; Devlin RD; Anderson JL; Craig F; Mundy GR; Roodman GD
    Blood; 1996 Feb; 87(4):1495-501. PubMed ID: 8608240
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Receptor activator of NF-kappaB ligand, macrophage inflammatory protein-1alpha, and the proteasome: novel therapeutic targets in myeloma.
    Oyajobi BO; Mundy GR
    Cancer; 2003 Feb; 97(3 Suppl):813-7. PubMed ID: 12548580
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Macrophage inflammatory protein-1 alpha is produced by human multiple myeloma (MM) cells and its expression correlates with bone lesions in patients with MM.
    Uneda S; Hata H; Matsuno F; Harada N; Mitsuya Y; Kawano F; Mitsuya H
    Br J Haematol; 2003 Jan; 120(1):53-5. PubMed ID: 12492576
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Ibandronate decreases bone disease development and osteoclast stimulatory activity in an in vivo model of human myeloma.
    Cruz JC; Alsina M; Craig F; Yoneda T; Anderson JL; Dallas M; Roodman GD
    Exp Hematol; 2001 Apr; 29(4):441-7. PubMed ID: 11301184
    [TBL] [Abstract][Full Text] [Related]  

  • 13. AML-1A and AML-1B regulation of MIP-1alpha expression in multiple myeloma.
    Choi SJ; Oba T; Callander NS; Jelinek DF; Roodman GD
    Blood; 2003 May; 101(10):3778-83. PubMed ID: 12560229
    [TBL] [Abstract][Full Text] [Related]  

  • 14. New insight in the mechanism of osteoclast activation and formation in multiple myeloma: focus on the receptor activator of NF-kappaB ligand (RANKL).
    Giuliani N; Colla S; Rizzoli V
    Exp Hematol; 2004 Aug; 32(8):685-91. PubMed ID: 15308315
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Bone lesions and macrophage inflammatory protein-1 alpha (MIP-1a) in human multiple myeloma.
    Hata H
    Leuk Lymphoma; 2005 Jul; 46(7):967-72. PubMed ID: 16019547
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Macrophage inflammatory protein 1-alpha is a potential osteoclast stimulatory factor in multiple myeloma.
    Choi SJ; Cruz JC; Craig F; Chung H; Devlin RD; Roodman GD; Alsina M
    Blood; 2000 Jul; 96(2):671-5. PubMed ID: 10887133
    [TBL] [Abstract][Full Text] [Related]  

  • 17. CCR1 chemokines promote the chemotactic recruitment, RANKL development, and motility of osteoclasts and are induced by inflammatory cytokines in osteoblasts.
    Yu X; Huang Y; Collin-Osdoby P; Osdoby P
    J Bone Miner Res; 2004 Dec; 19(12):2065-77. PubMed ID: 15537451
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Mechanisms for formation of myeloma bone disease].
    Yata K; Abe M; Matsumoto T
    Clin Calcium; 2008 Apr; 18(4):438-46. PubMed ID: 18379024
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Ability of myeloma cells to secrete macrophage inflammatory protein (MIP)-1alpha and MIP-1beta correlates with lytic bone lesions in patients with multiple myeloma.
    Hashimoto T; Abe M; Oshima T; Shibata H; Ozaki S; Inoue D; Matsumoto T
    Br J Haematol; 2004 Apr; 125(1):38-41. PubMed ID: 15015966
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Bone marrow plasma macrophage inflammatory protein protein-1 alpha(MIP-1 alpha) and sclerostin in multiple myeloma: relationship with bone disease and clinical characteristics.
    Wang XT; He YC; Zhou SY; Jiang JZ; Huang YM; Liang YZ; Lai YR
    Leuk Res; 2014 May; 38(5):525-31. PubMed ID: 24656650
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.